Comparison · NCT00093964-sae
Cilengitide 500 Milligram (mg) vs Cilengitide 2000 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cilengitide 500 Milligram (mg) vs Cilengitide 2000 mg: serious adverse events. Trial comparisons, record NCT00093964-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00093964-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.39 | 0.257 | 0.543 | wilson | |
| Risk in group 2 | 0.45 | 0.307 | 0.602 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0598 | -0.262 | 0.149 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.867 | 0.519 | 1.45 | log | |
| Odds ratio, group 1 over group 2 | 0.782 | 0.323 | 1.89 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Cilengitide 500 Milligram (mg) than on Cilengitide 2000 mg | 16.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cilengitide 500 Milligram (mg) | Subjects received 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent. | 16 | 41 | EG000 |
| Group 2 | Cilengitide 2000 mg | Subjects received 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent. | 18 | 40 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
- NCT number
- NCT00093964
- Phases
- PHASE2
- Conditions
- Glioblastoma Multiforme
- Interventions
- Cilengitide 500 mg, Cilengitide 2000 mg
- Lead sponsor
- EMD Serono
- Results first posted
- 2019-04-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00093964?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00093964-sae